Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide

Journal of Immunotherapy

Volumn 21, Issue 4, 1998, Pages 277-282

  Dubey, Purnima ^a   Meredith, Stephen C ^a   Siegel, Christopher T ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cytolytic T cells; Helicase; Immunodominant antigen; Mutant peptide; Point mutation

Indexed keywords

CD8 ANTIGEN; HELICASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; CANCER CELL; CANCER GROWTH; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION;

EID: 0031845292     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199807000-00005     Document Type: Article

References (18)

1. Schreiber H. Tumor immunology. In: Paul W, ed. Fundamental immunology. 3rd ed. New York: Raven Press, 1993:1143-78.
2. Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 1996;8: 289-93.
3. Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. JNCI 1993;85:1294-302.
4. + T cells. Proc Natl Acad Sci USA 1994;91:3171-5.
5. Basombrio MA. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 1970; 30:2458-62.
6. Carbone G, Borrello MG, Molla A, et al. Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int J Cancer 1991;47:619-25.
7. Brent L, Medawar P. Quantitative studies on tissue transplantation immunity. VIII. The effect of irradiation. Proc R Soc London [Biol] 1966;165:413-23.
8. Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989; 170:217-32.
9. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995;2:45-59.
10. Coulie PG, Lehmann F, Lethé B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976-80.
11. INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
12. Robbins PF, El-Gamil M, Li YF, et al. A. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
13. Brändle D, Brasseur F, Weynants P, Boon T, van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183:2501-8.
14. Dubey P, Hendrickson RC, Meredith SC, et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 1997;185:695-705.
15. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein chaperoned peptides. Science 1995; 269:1585-8.
16. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
17. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
18. + T cells in vivo. Proc Natl Acad Sci USA 1994;91:3077-81.